According to Union Health Minister Dr. Mansukh Mandaviya, a nasal vaccination against Covid-19 created by Bharat Biotech has been given the drug controller’s approval for “limited use” among adults “in emergency situations.” ChAd36-SARS-CoV-S from Bharat Biotech, The @CDSCO INDIA INF, has approved the COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine for primary vaccination against COVID-19 in the 18+ age group for only limited usage in emergency situations.

In February, Mumbai-based Glenmark and SaNOtize released a nasal spray (named FabiSpray) for the treatment of adult patients, making it the first anti-Covid medication in the nation. The company acquired manufacturing and marketing authorizations from the Drugs Controller General of India for its nitric oxide nasal spray as part of an expedited clearance process. The official release read, “Phase 3 study in India met the primary endpoints and exhibited a reduction of viral load of 94% in 24 hours and 994% in 48 hours.”

India reported a one-day increase of 4,417 coronavirus infections, which is the lowest in three months, according to government data updated at 8 am on Tuesday. There were 23 recorded fatalities while there were 52,336 fewer active Covid cases. According to the Health Ministry, the number of current cases now makes up 0.12% of all infections, while the recovery rate has grown to 98.69%. Worldwide, the development of vaccines is also gaining momentum. Also. the UK health officials approved a second “bivalent” vaccination on Saturday that will target the Omicron and original strains of the virus.

COVID-19 Causalities

The  pandemic in India was a component of the global coronavirus disease pandemic of 2019 (COVID-19), which was brought on by coronavirus 2, causing severe acute respiratory syndrome (SARS-CoV-2). Further, according to data from the Indian government, as of September 6, 2022, India has the second-highest number of confirmed COVID-19 cases in the world (after the United States of America), with 44,466,862 reported cases, and the third-highest number of COVID-19 deaths, with 528,030 deaths.

Continue to read more latest news

 235 total views,  1 views today